AMYVID
LOE Approachingflorbetapir f 18
NDAINTRAVENOUSSOLUTIONPriority Review
Approved
Apr 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Data completeness
3/8 — Basic
Priority Review
AMYVID (florbetapir f 18) is positron emitting activity [moa]. First approved in 2012.
Drug data last refreshed Just now · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMYVID (florbetapir F 18) is a positron-emitting radioactive diagnostic agent administered intravenously for PET imaging of beta-amyloid pathology in the brain. It is used to detect amyloid plaques in patients with cognitive impairment, supporting differential diagnosis of neurodegenerative diseases, particularly Alzheimer's disease. The drug works by binding to amyloid-beta deposits, allowing visualization via positron emission tomography.
LOE Approaching6mo to LOE
LOE approaching in 2027 signals contraction of brand team and shift toward lifecycle management or divestment.
Mechanism of Action
Positron Emitting Activity
Pharmacologic Class:
Radioactive Diagnostic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Patent cliff in less than a year — expect lifecycle management and generic defense hiring
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.